PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy - Tarantelli, C., Gaudio, E., Arribas, A. J., Kwee, I., Hillmann, P., Rinaldi, A., Cascione, L., Spriano, F., Bernasconi, E., Guidetti, F., Carrassa, L., Pittau, R. B., Beaufils, F., Ritschard, R., Rageot, D., Sele, A., Dossena, B., Rossi, F. M., Zucchetto, A., Taborelli, M., Gattei, V., Rossi, D., Stathis, A., Stussi, G., Broggini, M., Wymann, M. P., Wicki, A., Zucca, E., Cmiljanovic, V., Fabbro, D., Bertoni, F. (The American Association for Cancer Research (AACR), 2018)
6128580